Bronchiolitis vaccine: Pfizer announces positive results for children – Le Figaro

According to these findings, the vaccine was found to be about 82% effective in preventing severe cases in the baby’s first three months, and about 69% in the following six months.

American group Pfizer On Tuesday, positive results for newborns and infants were announced from a clinical trial of a vaccine against respiratory syncytial virus (RSV) that causes bronchiolitis, given to mothers during pregnancy.

According to these Phase 3 test results revealed by the company, the vaccine was found to be approximately 82% effective in preventing serious cases in the baby’s first three months, and about 69% within six months. However, the trial did not conclude that the vaccine reduces non-severe cases significantly. ‘Statistically significant’even if tests show some clinical efficacy, refers to the laboratory.

Based on these findings, which have not been reviewed by independent scientists, Pfizer plans to obtain a license for the vaccine in pregnant women by the end of the year in the United States and then in other countries.

Bronchiolitis is a very common and contagious respiratory disease, especially in infants from 2 to 8 months of age, that causes coughing and difficulty breathing. Most of the time, the disease is mild. But it may require a trip to the emergency room, or even hospitalization. Pfizer estimates that around 102,000 babies die from RSV each year worldwide, half of them under six months of age.

Usually, the epidemic of bronchiolitis begins between the end of October and the middle of November, reaches its peak in December, and ends at the end of January or even the end of February. But This year started earlier than usual in many countries.

Sanofi and Astrazeneca in September obtained a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for nirsevimab, which aims to protect infants throughout the virus circulating season.

It is called Bifortus, and it differs from vaccines that use traditional techniques because it is a monoclonal antibody, that is, an antibody developed in the laboratory, which makes it possible to confer so-called passive immunity to the infant, in a single dose. The European Commission has yet to give the go-ahead for its commercialization.

Other pharmaceutical groups are also working on vaccines against RSV, including Britain’s GSK and American’s Moderna and Johnson & Johnson. Pfizer had already announced positive results for the vaccine for seniors in August.


see also Bronchiolitis epidemic: 31 children transferred to intensive care outside Ile-de-France

#Bronchiolitis #vaccine #Pfizer #announces #positive #results #children #Figaro

Leave a Comment

Your email address will not be published.